Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

An injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.

Morrisons has opened its own weight loss subscription, selling tirzepatide injections – also known as Mounjaro – to help ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

While tirzepatide has been on the market to treat type 2 diabetes under the name Mounjaro, Zepbound was just FDA approved for weight loss and most health insurances don’t cover it as a result ...

Diabetes drug Tirzepatide, which is shown to be more effective than Wegovy and Ozempic, is likely to be approved by the Food and Drug Administration for weight loss in 2023 and is expected to be ...

Tirzepatide and injectable semaglutide were associated with the greatest weight loss after a year of treatment among several GLP-1 receptor agonists, a recent study showed.“Despite being the ...